Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RYTM 
Rhythm Pharmaceuticals Inc (RYTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RYTM (4-star) is a STRONG-BUY. BUY since 85 days. Profits (60.43%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $112.5
1 Year Target Price $112.5
| 8 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 80.29% | Avg. Invested days 35 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.41B USD | Price to earnings Ratio - | 1Y Target Price 112.5 |
Price to earnings Ratio - | 1Y Target Price 112.5 | ||
Volume (30-day avg) 12 | Beta 2.39 | 52 Weeks Range 43.57 - 99.04 | Updated Date 08/15/2025 |
52 Weeks Range 43.57 - 99.04 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.67 | Actual -0.75 |
Profitability
Profit Margin -117.16% | Operating Margin (TTM) -93.39% |
Management Effectiveness
Return on Assets (TTM) -29.39% | Return on Equity (TTM) -116.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6266862379 | Price to Sales(TTM) 41 |
Enterprise Value 6266862379 | Price to Sales(TTM) 41 | ||
Enterprise Value to Revenue 40.1 | Enterprise Value to EBITDA -12.65 | Shares Outstanding 66420100 | Shares Floating 54280491 |
Shares Outstanding 66420100 | Shares Floating 54280491 | ||
Percent Insiders 0.65 | Percent Institutions 103.85 |
Upturn AI SWOT
Rhythm Pharmaceuticals Inc
Company Overview
History and Background
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2008. It focuses on developing and commercializing therapies for rare genetic diseases of obesity. A significant milestone was the FDA approval of IMCIVREE for certain rare genetic forms of obesity.
Core Business Areas
- Rare Genetic Obesity: Development and commercialization of therapies for rare genetic diseases of obesity, such as POMC, LEPR, PCSK1, and POMC deficiencies.
Leadership and Structure
David Meeker, M.D. is the current CEO. The organizational structure includes departments focused on research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- IMCIVREE (setmelanotide): IMCIVREE is a melanocortin-4 receptor (MC4R) agonist approved for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing, and Bardet-Biedl syndrome (BBS). Rhythm holds a significant market share in the rare genetic obesity market, which is relatively niche. Competitors are primarily focused on broader obesity markets, such as Novo Nordisk (Wegovy, Saxenda) and Eli Lilly (Zepbound).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on obesity is growing, with increasing awareness of obesity as a chronic disease. The rare genetic obesity subsegment is specialized and requires precise diagnosis and targeted therapies.
Positioning
Rhythm Pharmaceuticals is a leader in the rare genetic obesity market with a targeted therapy. Its competitive advantage lies in its specific focus and approved product for these rare conditions.
Total Addressable Market (TAM)
The TAM for rare genetic obesity is estimated to be significant, considering the prevalence of genetic disorders and the high cost of therapies. Rhythm is positioned to capture a substantial portion of this market through its approved therapies and ongoing research and development.
Upturn SWOT Analysis
Strengths
- FDA-approved targeted therapy (IMCIVREE)
- First-mover advantage in rare genetic obesity
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Reliance on a single product (IMCIVREE)
- High research and development costs
- Limited market size (rare genetic conditions)
- Commercial execution in a small patient population
Opportunities
- Expansion of IMCIVREE label to other genetic obesity conditions
- Development of new therapies for related metabolic disorders
- Partnerships with diagnostic companies to improve patient identification
- Geographic expansion
Threats
- Competition from larger pharmaceutical companies entering the obesity market
- Potential for generic or biosimilar competition
- Regulatory changes affecting drug approval or reimbursement
- Clinical trial failures
Competitors and Market Share
Key Competitors
- NVO
- LLY
- VKTX
Competitive Landscape
Rhythm Pharmaceuticals competes primarily with larger pharmaceutical companies in the broader obesity market, but it has a niche position in rare genetic obesity. Its advantage lies in its targeted therapy and first-mover status, while its disadvantage is its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the commercialization of IMCIVREE.
Future Projections: Future growth is projected to be driven by label expansion, geographic expansion, and the development of new therapies.
Recent Initiatives: Recent initiatives include clinical trials for new indications of IMCIVREE and partnerships to enhance patient identification.
Summary
Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare genetic obesity, with IMCIVREE as its key product. Its strength lies in its targeted therapy and first-mover advantage. The company faces challenges related to market size and competition from larger players. Future growth depends on label expansion, geographic expansion, and new therapy development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rhythm Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-10-05 | Chairman, President & CEO Dr. David P. Meeker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 283 | Website https://rhythmtx.com |
Full time employees 283 | Website https://rhythmtx.com | ||
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.